This research is being done to develop the electronic platform Nest for young adults (ages 18-39) who have had prior cancer genetic testing. The platform will give patients and their clinicians access to continuously updated information about both pathogenic variants and variants of uncertain significance (VUS).

The name of the intervention used in this research study is:

Nest portal (electronic platform for patients and clinicians)

The goal of the electronic platform Nest is to help patients understand and manage genetic test results and recommended care and to help clinicians with access to results and recommendations, facilitating orders, and documentation. The portal has two parts, one for participants and one for clinicians.

For the first phase of the study, participants will give their feedback on the Nest portal's content and processes that will guide refinement of the portal. The Pilot phase will test the feasibility and acceptability of the intervention.

The research study procedures include a baseline survey, using the portal after receiving a brief orientation from the study team, a follow-up survey, and then a 30-minute interview.

Participants will be in this research study for up to 2 hours.

It is expected that about 40 people will take part in this research study.

The electronic platform is being developed by Nest Genomics.

Inclusion Criteria AIM 1:

• YA Patients:

  • Ages 18-39 years, inclusive.
  • Has had previous cancer genetic testing, with a finding of a pathogenic variant or VUS; patient has previously received results from the clinical team.
  • English-speaking and -reading.
  • Receiving care at DFCI.
  • Not undergoing active cancer therapy at the time of approach.

• Clinicians:

  • Cancer risk physicians (oncologists, gastroenterologists, geneticists), oncologists, nurse practitioners, physician assistants, or genetic counselors.
  • English-speaking and -reading.
  • Cares for YAs aged 18-39 with cancer risk syndromes.

Inclusion Criteria AIM 2:

• YA Patients:

  • Ages 18-39 years, inclusive.
  • Has had previous cancer genetic testing, with a finding of a pathogenic variant or VUS; patient has previously received results from the clinical team.
  • English-speaking and -reading.
  • Receiving care at Dana-Farber Cancer Institute.
  • Did not participate in a stakeholder interview (Aim 1).
  • Not undergoing active cancer therapy at the time of approach.

• Clinicians:

  • Oncologists, nurse practitioners, cancer risk physicians, or genetic counselors.
  • English-speaking and -reading.
  • Caring for a participating YA.

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Data can be shared no earlier than 1 year following the date of publication

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu